Ipamorelin: Selective Ghrelin Receptor (GHS-R1a) Agonism & Pulsatile Growth Hormone Release

Ipamorelin possesses the chemical sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, representing a meticulously engineered peptide backbone designed to resist rapid enzymatic hydrolysis by serum peptidases while maximizing steric complementarity to the binding pocket of the human GHS-R1a receptor.

The substitution of α-aminoisobutyric acid (Aib) at the N-terminus and D-stereoisomers at positions 3 and 4 confers robust proteolytic resistance against dipeptidyl peptidase IV (DPP-4) and aminopeptidases, granting Ipamorelin a plasma elimination half-life of approximately 2 hours in mammalian models—substantially longer than native ghrelin (half-life ~10-15 minutes).

With a monoisotopic molecular weight of 711.86 Da, Ipamorelin exists as an amphiphilic white lyophilized powder that readily dissolves in aqueous solvents, forming clear, non-aggregating solutions under neutral pH conditions.

Upon binding to the transmembrane G-protein coupled receptor GHS-R1a on somatotroph membranes of the anterior pituitary gland, Ipamorelin initiates a Gαq/11 signaling cascade. This triggers phospholipase C (PLC) activation, catalyzing the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).

IP3 diffuses to the endoplasmic reticulum, binding to IP3 receptors and prompting rapid mobilization of intracellular calcium stores. Concurrently, protein kinase C (PKC) activation induces closure of voltage-gated potassium channels, depolarizing the somatotroph membrane and opening L-type calcium channels. The resultant influx of extracellular calcium drives exocytic vesicle fusion, releasing pre-formed GH granules into circulation.

Crucially, radioligand binding studies demonstrate that Ipamorelin does not activate dopamine, opioid, or adrenergic receptors, explaining its complete lack of hyperprolactinemia or autonomic instability.

First-generation GH secretagogues (such as GHRP-6 and GHRP-2) are notorious for cross-reacting with hypothalamic corticotropin-releasing hormone (CRH) pathways, leading to dose-dependent elevations in ACTH, systemic cortisol, and prolactin. In longitudinal research models, prolonged hypercortisolemia induces catabolic muscle wasting, immune suppression, and insulin resistance.

Ipamorelin was structurally engineered to eliminate this cross-reactivity. In classic in-vivo porcine and rodent bioassays by Raun et al., escalating doses of Ipamorelin up to 50 times the ED50 elicited robust, dose-dependent growth hormone spikes while plasma cortisol and prolactin remained indistinguishable from baseline saline vehicle controls.

This unique endocrine fidelity establishes Ipamorelin as the benchmark reference standard for selective GH secretagogue research where unperturbed baseline adrenal and gonadal axes are required.

The downstream endocrine mediator of Ipamorelin-induced GH release is hepatic insulin-like growth factor 1 (IGF-1). Elevated circulating and paracrine IGF-1 stimulates the PI3K/Akt and MAPK/ERK pathways in peripheral tissues, stimulating skeletal muscle protein synthesis and osteoblast differentiation.

In longitudinal animal studies of osteopenia and bone demineralization, 12 weeks of daily Ipamorelin administration resulted in significant increases in cortical bone thickness, trabecular volumetric bone mineral density (vBMD), and mechanical loading strength compared to untreated controls.

Additionally, Ipamorelin enhances nitrogen balance in catabolic models, attenuating the muscle-wasting effects of prolonged glucocorticoid therapy or immobilized recovery states.

For analytical and in-vitro laboratory investigations, Ipamorelin lyophilized cake must be reconstituted with 0.9% USP grade bacteriostatic sodium chloride (0.9% benzyl alcohol preservative) or sterile water for injection (SWFI).

Recommended reconstitution volume is 2.0 mL of bacteriostatic diluent per 2mg or 5mg vial, gently directed down the inner glass wall of the borosilicate vial to minimize shear force denaturation. The vial should be swirled gently—never vortexed or shaken vigorously.

Reconstituted Ipamorelin must be shielded from ultraviolet photolysis and maintained in refrigerated storage at 2°C–8°C. Analytical stability testing confirms ≥98.5% peptide purity is preserved across 28 days of refrigerated storage.

Ipamorelin reference standard produced by Pepstack Labs conforms to strict analytical monograph specifications: purity ≥99.0% by reverse-phase high-performance liquid chromatography (RP-HPLC), mass identity verification by electrospray ionization mass spectrometry (ESI-MS, observed m/z 712.38 [M+H]+), and residual bacterial endotoxins <0.05 EU/mg by kinetic chromogenic LAL assay.

Storage Conditions: Store dry lyophilized powder at -20°C in an airtight container protected from desiccants and light for up to 24 months.

Regulatory & Safety Statement: This compound is synthesized and supplied strictly for in-vitro laboratory research, pharmacological profiling, and receptor binding assays. Not for human, veterinary, therapeutic, or cosmetic consumption.